Updated strategies for the management of poor medication adherence in patients with bipolar disorder

References

• Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;2:1465–1858.
   Google Scholar
• WHO. Adherence to long-term therapies: evidence for action. Geneva Switzerland: World Health Organization; 2003p. 3.
   Google Scholar
• Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016 Mar;30(6):495–553.
   PubMed Web of Science ®Google Scholar
• Prajapati AR, Dima A, Mosa G, et al. Mapping modifiable determinants of medication adherence in bipolar disorder (BD) to the theoretical domains framework (TDF): a systematic review. Psychol Med. 2021 May;51(7):1082–1098.
   PubMedGoogle Scholar
• Colom F, Vieta E, Martinez-Aran A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients [Clinical Trial comparative study research support, Non-U.S. Gov’t]. J Clin Psychiatry. 2000 Aug;61(8):549–555.
   PubMedGoogle Scholar
• Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder [Research Support, N.I.H., Extramural]. Bipolar Disord. 2006 Jun;8(3):232–241.
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002 Mar;105(3):164–172.
   PubMed Web of Science ®Google Scholar
• Licht RW, Vestergaard P, Rasmussen NA, et al. A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients. Acta Psychiatr Scand. 2001 Nov;104(5):387–390.
   PubMedGoogle Scholar
• Bohlken J, Konrad M, Kostev K. Adherence to neuroleptic treatment in psychiatric practices: a retrospective study of 55 practices with more than 5000 bipolar and schizophrenic patients in Germany. Psychiatry Res. 2020 Feb;284:112758.
   PubMedGoogle Scholar
• Greene M, Paladini L, Lemmer T, et al. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA. Neuropsychiatr Dis Treat. 2018;14:1545–1559.
   PubMed Web of Science ®Google Scholar
• Consoloni JL, M’bailara K, Perchec C, et al. Trajectories of medication adherence in patients with Bipolar Disorder along 2 years-follow-up. J Affect Disord. 2021 Mar 1;282:812–819. DOI:10.1016/j.jad.2020.12.192
   PubMedGoogle Scholar
• Levin JB, Tatsuoka C, Cassidy KA, et al. Trajectories of medication attitudes and adherence behavior change in non-adherent bipolar patients. Compr Psychiatry. 2015 Apr;58:29–36.
   PubMed Web of Science ®Google Scholar
• Doane MJ, Ogden K, Bessonova L, et al. Real-world patterns of utilization and costs associated with second-generation oral antipsychotic medication for the treatment of bipolar disorder: a literature review. Neuropsychiatr Dis Treat. 2021;17:515–531.
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry. 1998 May;155(5):646–652.
   PubMed Web of Science ®Google Scholar
• Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm. 2009 Feb 15;66(4):358–365.
   PubMedGoogle Scholar
• Li C, Chen C, Qiu B, et al. A 2-year follow-up study of discharged psychiatric patients with bipolar disorder. Psychiatry Res. 2014 Aug;218(1–2):75–78.
   PubMedGoogle Scholar
• Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry. 2002 Nov;159(11):1927–1929.
   PubMed Web of Science ®Google Scholar
• Hong J, Reed C, Novick D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res. 2011 Nov 30;190(1):110–114. DOI:10.1016/j.psychres.2011.04.016
   PubMedGoogle Scholar
• Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006 Oct;8(5 Pt 2):618–624.
   PubMed Web of Science ®Google Scholar
• Müller-Oerlinghausen B, Wolf T, Ahrens B, et al. Mortality of patients who dropped out from regular lithium prophylaxis: a collaborative study by the International Group for the Study of Lithium-treated patients (IGSLI). Acta Psychiatr Scand. 1996 Nov;94(5):344–347.
   PubMedGoogle Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001 Jun;52(6):805–811.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1–46. DOI:10.4088/JCP.7090su1cj
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002 May;63(5):384–390.
   PubMedGoogle Scholar
• Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry. 2009 Mar;50(2):100–107.
   PubMedGoogle Scholar
• Voils CI, Maciejewski ML, Hoyle RH, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med care. 2012 Dec;50(12):1013–1019.
   PubMed Web of Science ®Google Scholar
• Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level. J Clin Psychopharmacol. 2010 Apr;30(2):169–175.
   PubMed Web of Science ®Google Scholar
• Busby KK, Sajatovic M. REVIEW: patient, treatment, and systems-level factors in bipolar disorder nonadherence: a summary of the literature [Review]. CNS Neurosci Ther. 2010 Oct;16(5):308–315.
   PubMedGoogle Scholar
• Sajatovic M, Chen PJ, Dines P, et al. Psychoeducational approaches to medication adherence in patients with bipolar disorder. Dis Manag Health Out. 2007;15(3):181–192. DOI:10.2165/00115677-200715030-00006
   Google Scholar
• Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005 Feb;133(2–3):129–133.
   PubMed Web of Science ®Google Scholar
• Koschack J, Marx G, Schnakenberg J, et al. Comparison of two self-rating instruments for medication adherence assessment in hypertension revealed insufficient psychometric properties. J Clin Epidemiol. 2010 Mar;63(3):299–306.
   PubMedGoogle Scholar
• De Las Cuevas C, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. Int J Clin Health Psychol. 2015;15(2):121–129.
   PubMed Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000 May;42(3):241–247.
   PubMed Web of Science ®Google Scholar
• Bauer M, Glenn T, Alda M, et al. Regularity in daily mood stabilizer dosage taken by patients with bipolar disorder. Pharmacopsychiatry. 2013 Jul;46(5):163–168.
   PubMedGoogle Scholar
• Pilhatsch M, Glenn T, Rasgon N, et al. Regularity of self-reported daily dosage of mood stabilizers and antipsychotics in patients with bipolar disorder. Int J Bipolar Disord. 2018 May 1;6(1):10. DOI:10.1186/s40345-018-0118-8
   PubMedGoogle Scholar
• Levin JB, Sajatovic M, Rahman M, et al. Outcomes of psychoeducation and a text messaging adherence intervention among individuals with hypertension and bipolar disorder. Psychiatric Serv. 2019 Apr;70(7):appips201800482.
   Google Scholar
• Moore DJ, Poquette A, Casaletto KB, et al. Individualized texting for adherence building (iTAB): improving antiretroviral dose timing among HIV-infected persons with co-occurring bipolar disorder. AIDS Behav. 2015 Mar;19(3):459–471.
   PubMed Web of Science ®Google Scholar
• Berk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol. 2010 Jan;25(1):1–16.
   PubMed Web of Science ®Google Scholar
• Velligan DI, Kamil SH. Enhancing patient adherence: introducing smart pill devices. Ther Deliv. 2014 Jun;5(6):611–613.
   PubMedGoogle Scholar
• Levin JB, Sams J, Tatsuoka C, et al. Use of automated medication adherence monitoring in bipolar disorder research: pitfalls, pragmatics, and possibilities. Ther Adv Psychopharmacol. 2015 Apr;5(2):76–87.
   PubMedGoogle Scholar
• Sajatovic M, Velligan DI, Weiden PJ, et al. Measurement of psychiatric treatment adherence [Research Support N.I.H., Extramural Review]. J Psychosom Res. 2010 Dec;69(6):591–599.
   PubMed Web of Science ®Google Scholar
• van Onzenoort HA, Neef C, Verberk WW, et al. Determining the feasibility of objective adherence measurement with blister packaging smart technology. Am J Health Syst Pharm. 2012 May;69(10):872–879.
   PubMedGoogle Scholar
• Sajatovic <, Tatsuoka <, Cassidy <, et al. A 6-month, prospective, randomized controlled trial of customized adherence enhancement versus bipolar-specific educational control in poorly adherent individuals with bipolar disorder. J Clin Psychiatry. 2018 Sep;79(6). DOI: 10.4088/JCP.17m12036
   Google Scholar
• Levin <, Krivenko <, Howland <, et al. Medication adherence in patients with bipolar disorder: a comprehensive review. CNS Drugs. 2016 Sep;30(9):819–35. DOI:10.1007/s40263-016-0368-x
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatric Serv. 2004 Mar;55(3):264–269.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013 Jul;149(1–3):247–252.
   PubMed Web of Science ®Google Scholar
• Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother. 2013 Jul;13(7):809–825.
   PubMed Web of Science ®Google Scholar
• Hou R, Cleak V, Peveler R. Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study. Eur Psychiatry. 2010 May;25(4):216–219.
   PubMedGoogle Scholar
• Barraco A, Rossi A, Nicolò G, et al. Description of study population and analysis of factors influencing adherence in the observational Italian study “Evaluation of Pharmacotherapy Adherence in Bipolar Disorder (EPHAR). CNS Neurosci Ther. 2012 Feb;18(2):110–118.
   PubMedGoogle Scholar
• Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol. 2008 Mar;23(2):95–105.
   PubMed Web of Science ®Google Scholar
• Lang K, Korn J, Muser E, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ. 2011;14(2):217–226. DOI:10.3111/13696998.2011.562265
   PubMedGoogle Scholar
• Sajatovic M, Levin J, Fuentes-Casiano E, et al. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry. 2011 May;52(3):280–287.
   PubMedGoogle Scholar
• Sajatovic M, Blow FC, Kales HC, et al. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. Int J Geriatr Psychiatry. 2007 Oct;22(10):992–998.
   PubMedGoogle Scholar
• Casaletto KB, Kwan S, Montoya JL, et al. Predictors of psychotropic medication adherence among HIV+ individuals living with bipolar disorder. Int J Psychiatry Med. 2016;51(1):69–83. DOI:10.1177/0091217415621267
   PubMed Web of Science ®Google Scholar
• González-Pinto A, Reed C, Novick D, et al. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry. 2010 Nov;43(7):263–270.
   PubMedGoogle Scholar
• Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder [Research Support N.I.H., Extramural Research Support, U.S. Gov’t, Non-P.H.S.]. Psychiatric Services. 2007 Jun;58(6):855–863.
   PubMedGoogle Scholar
• Fuller M, Sajatovic M. Drug information handbook for psychiatry. 7th ed. Cleveland OH: Lexi-Comp; 2009.
   Google Scholar
• Arvilommi P, Suominen K, Mantere O, et al. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study. J Affect Disord. 2014 Feb;155:110–117.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders [Review]. Bipolar Disord. 2005;7(Suppl 5):24–31. DOI:10.1111/j.1399-5618.2005.00248.x
   PubMed Web of Science ®Google Scholar
• Chakrabarti S. Treatment attitudes and adherence among patients with bipolar disorder: a systematic review of quantitative and qualitative studies. Harv Rev Psychiatry. 2019 Sep;27(5):290–302.
   PubMedGoogle Scholar
• Averous P, Charbonnier E, Lagouanelle-Simeoni MC, et al. Illness perceptions and adherence in bipolar disorder: an exploratory study. Compr Psychiatry. 2018 Jan;80:109–115.
   PubMedGoogle Scholar
• Zeber JE, Miller AL, Copeland LA, et al. Medication adherence, ethnicity, and the influence of multiple psychosocial and financial barriers. Adm Policy Ment Health. 2011 Mar;38(2):86–95.
   PubMedGoogle Scholar
• Alcalá J, Fontalba-Navas A, Company-Morales M, et al. Facilitators and barriers of medication adherence based on beliefs of persons with bipolar disorder: a qualitative study. Int J Environ Res Public Health. 2022 Jun 22;19(13):7633. DOI:10.3390/ijerph19137633
   PubMedGoogle Scholar
• Faurholt-Jepsen M, Frost M, Christensen EM, et al. Validity and characteristics of patient-evaluated adherence to medication via smartphones in patients with bipolar disorder: exploratory reanalyses on pooled data from the MONARCA I and II trials. Evid Based Ment Health. 2020 Feb;23(1):2–7.
   PubMedGoogle Scholar
• Selvakumar N, Menon V, Kattimani S. A cross-sectional analysis of patterns and predictors of medication adherence in bipolar disorder: single center experience from South India. Clin Psychopharmacol Neurosci. 2018 May 31;16(2):168–175.
   PubMedGoogle Scholar
• Danion JM, Neunreuther C, Krieger-Finance F, et al. Compliance with long-term lithium treatment in major affective disorders. Pharmacopsychiatry. 1987 Sep;20(5):230–231.
   PubMedGoogle Scholar
• Sajatovic M, Micula-Gondek W, Tatsuoka C, et al. The relationship of gender and gender identity to treatment adherence among individuals with bipolar disorder. Gender med. 2011 Aug;8(4):261–268.
   PubMedGoogle Scholar
• Maarbjerg K, Aagaard J, Vestergaard P. Adherence to lithium prophylaxis: i. Clinical predictors and patient’s reasons for nonadherence. Pharmacopsychiatry. 1988 May;21(3):121–125.
   PubMedGoogle Scholar
• Murru A, Pacchiarotti I, Amann BL, et al. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord. 2013 Dec;151(3):1003–1008.
   PubMed Web of Science ®Google Scholar
• Kessing LV, Søndergård L, Kvist K, et al. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord. 2007 Nov;9(7):730–736.
   PubMed Web of Science ®Google Scholar
• Belzeaux R, Correard N, Boyer L, et al. Depressive residual symptoms are associated with lower adherence to medication in bipolar patients without substance use disorder: results from the FACE-BD cohort. J Affect Disord. 2013 Dec;151(3):1009–1015.
   PubMedGoogle Scholar
• Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics [Comparative Study Research Support, Non-U.S. Gov’t]. J Clin Psychiatry. 2006 Feb;67(2):222–232.
   PubMedGoogle Scholar
• Cochran SD, Gitlin MJ. Attitudinal correlates of lithium compliance in bipolar affective disorders. J Nerv Ment Dis. 1988 Aug;176(8):457–464.
   PubMed Web of Science ®Google Scholar
• Klein CC, Topalian <, Starr <, et al. The importance of second-generation antipsychotic-related weight gain and adherence barriers in youth with bipolar disorders: patient, parent, and provider perspectives. J Child Adolesc Psychopharmacol. 2020 Jul;30(6):376–380.
   PubMedGoogle Scholar
• Mousavi N, Norozpour M, Taherifar Z, et al. Bipolar I disorder: a qualitative study of the viewpoints of the family members of patients on the nature of the disorder and pharmacological treatment non-adherence. BMC Psychiatry. 2021 Feb 8;21(1):83. DOI:10.1186/s12888-020-03008-x
   PubMedGoogle Scholar
• Fung VC, Overhage LN, Sylvia LG, et al. Complex polypharmacy in bipolar disorder: side effect burden, adherence, and response predictors. J Affect Disord. 2019 Oct 1;257:17–22. DOI:10.1016/j.jad.2019.06.050
   PubMedGoogle Scholar
• Bauer M, Glenn T, Alda M, et al. Drug treatment patterns in bipolar disorder: analysis of long-term self-reported data. Int J Bipolar Disord. 2013;1:5.
   PubMedGoogle Scholar
• Sylvia LG, Hay A, Ostacher MJ, et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol. 2013 Jun;33(3):343–350.
   PubMedGoogle Scholar
• Wilder CM, Elbogen EB, Moser LL, et al. Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. Psychiatric Serv. 2010 Apr;61(4):380–385.
   PubMedGoogle Scholar
• Johnson FR, Ozdemir S, Manjunath R, et al. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med care. 2007 Jun;45(6):545–552.
   PubMed Web of Science ®Google Scholar
• Basco M, Smith J. Faulty decision-making: impact on treatment adherence in bipolar disorder. Primary Psychiatry. 2009;16(8):53–58.
   Google Scholar
• Andrade-González N, Hernández-Gómez A, Álvarez-Sesmero S, et al. The influence of the working alliance on the treatment and outcomes of patients with bipolar disorder: a systematic review. J Affect Disord. 2020 Jan 1;260:263–271. DOI:10.1016/j.jad.2019.09.014.
   PubMedGoogle Scholar
• Sajatovic M, Levin JB, Ramirez LF, et al. Long-acting injectable antipsychotic medication plus customized adherence enhancement in poor adherence patients with bipolar disorder. Prim Care Companion CNS Disord. 2021 Sep 16;23(5). DOI:10.4088/PCC.20m02888
   PubMedGoogle Scholar
• McVoy M, Delbello M, Levin J, et al. A customized adherence enhancement program for adolescents and young adults with suboptimal adherence and bipolar disorder: trial design and methodological report. Contemp Clin Trials. 2022 04;115:106729. DOI:10.1016/j.cct.2022.106729
   PubMedGoogle Scholar
• Goldstein TR, Krantz ML, Fersch-Podrat RK, et al. A brief motivational intervention for enhancing medication adherence for adolescents with bipolar disorder: a pilot randomized trial. J Affect Disord. 2020;265:1–9.
   PubMedGoogle Scholar
• Rahmani F, Ebrahimi H, Ranjbar F, et al. The effect of group psychoeducation program on medication adherence in patients with bipolar mood disorders: a randomized controlled trial. J Caring Sci. 2016 Dec;5(4):287–297.
   PubMedGoogle Scholar
• Pakpour <, Modabbernia <, Lin <, et al. Promoting medication adherence among patients with bipolar disorder: a multicenter randomized controlled trial of a multifaceted intervention. Psychol Med. 2017 Oct;47(14):2528–2539. DOI:10.1017/S003329171700109X
   PubMed Web of Science ®Google Scholar
• Mishra A, Krishna GS, Alla S, et al. Impact of Pharmacist-Psychiatrist Collaborative Patient Education on Medication adherence and Quality of Life (QOL) of Bipolar Affective Disorder (BPAD)patients. Front Pharmacol. 2017;8:722.
   PubMedGoogle Scholar
• Balikai SI, Rentala S, Mudakavi IB, et al. Impact of nurse-led medication adherence therapy on bipolar affective disorder: a randomized controlled trial. Perspect Psychiatr Care. 2022 May 13;58(4):2676–2686. DOI:10.1111/ppc.13108
   PubMedGoogle Scholar
• Başkaya E, Demir S. Effect of treatment adherence training given to patients with bipolar disorder on treatment adherence, social functioning and quality of life: a pilot study. Complement Ther Clin Pract. 2022 Feb;46:101504.
   PubMedGoogle Scholar
• Colom F, Vieta E, Sanchez-Moreno J, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Br J Psychiatry. 2009 Mar;194(3):260–5. DOI:10.1192/bjp.bp.107.040485
   PubMed Web of Science ®Google Scholar
• Etain B, Scott J, Cochet B, et al. A study of the real-world effectiveness of group psychoeducation for bipolar disorders: is change in illness perception a key mediator of benefit? J Affect Disord. 2018 02;227: 713–720. DOI:10.1016/j.jad.2017.11.072
   PubMed Web of Science ®Google Scholar
• Menon V, Selvakumar N, Kattimani S, et al. Therapeutic effects of mobile-based text message reminders for medication adherence in bipolar I disorder: are they maintained after intervention cessation? J Psychiatr Res. 2018 09;104: 163–168. DOI:10.1016/j.jpsychires.2018.07.013
   PubMed Web of Science ®Google Scholar
• Levin JB, Moore DJ, Depp C, et al. Using mHealth to improve adherence and reduce blood pressure in individuals with hypertension and bipolar disorder (iTAB-CV): study protocol for a 2-stage randomized clinical trial. Trials. 2022 Jun 29;23(1):539. DOI:10.1186/s13063-022-06449-9
   PubMedGoogle Scholar
• Maurin KD, Girod C, Consolini JL, et al. Use of a serious game to strengthen medication adherence in euthymic patients with bipolar disorder following a psychoeducational programme: a randomized controlled trial. J Affect Disord. 2020 02;262: 182–188. DOI:10.1016/j.jad.2019.10.008
   PubMedGoogle Scholar
• Kopelowicz A, Baker RA, Zhao C, et al. A multicenter, open-label, pilot study evaluating the functionality of an integrated call center for a digital medicine system to optimize monitoring of adherence to oral aripiprazole in adult patients with serious mental illness. Neuropsychiatr Dis Treat. 2017;13:2641–2651. .
   PubMed Web of Science ®Google Scholar
• Kim AM, Salstein L, Goldberg JF. A systematic review of complex polypharmacy in bipolar disorder: prevalence, clinical features, adherence, and preliminary recommendations for practitioners. J Clin Psychiatry. 2021 Jun 1;82(3). DOI:10.4088/JCP.20r13263.
   Google Scholar
• Wingård L, Brandt L, Bodén R, et al. Monotherapy vs. combination therapy for post mania maintenance treatment: a population based cohort study. Eur Neuropsychopharmacol. 2019 Jun;29(6):691–700.
   PubMedGoogle Scholar
• Peselow ED, Naghdechi L, Pizano D, et al. Polypharmacy in maintenance of bipolar disorder. Clin Neuropharmacol. 2016 May;39(3):132–134.
   PubMedGoogle Scholar
• Barbuti M, Colombini P, Ricciardulli S, et al. Treatment adherence and tolerability of immediate- and prolonged-release lithium formulations in a sample of bipolar patients: a prospective naturalistic study. Int Clin Psychopharmacol. 2021 09;36(5):230–237. DOI:10.1097/YIC.0000000000000373
   PubMed Web of Science ®Google Scholar
• Martinotti G, Pettorruso M, De Berardis D, et al. Clinical use of lithium and new retard formulation: results of a survey on Italian psychiatrists. Riv Psichiatr. 2020 Sep;55(5):269–280.
   PubMedGoogle Scholar
• Carter BL, Bergus GR, Dawson JD, et al. A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich). 2008 Apr;10(4):260–271.
   PubMed Web of Science ®Google Scholar
• Libby AM, Fish DN, Hosokawa PW, et al. Patient-level medication regimen complexity across populations with chronic disease. Clin Ther. 2013 Apr;35(4):385–398.e1.
   PubMed Web of Science ®Google Scholar
• Greene M, Yan T, Chang E, et al. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder. J Med Econ. 2018 Feb;21(2):127–134.
   PubMed Web of Science ®Google Scholar
• Yan <, Greene <, Chang <, et al. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar i disorder: a real-world study using US claims data. Adv Ther. 2018 Oct;35(10):1612–1625. DOI: 10.1007/s12325-018-0785-y
   PubMed Web of Science ®Google Scholar
• National Library of medicine (US) [Internet]. Bethesda MD: National Center for Biotechnology Information. [cited 21 Feb 2023]. Available from: https://www.ncbi.nlm.nih.gov/.
   Google Scholar
• Bartoli F, Bachi B, Calabrese A, et al. Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: a retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study. J Affect Disord. 2022 Sep 1;318:88–93. DOI:10.1016/j.jad.2022.08.096
   PubMedGoogle Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Kessing LV. Should long-acting injectable antipsychotics be used earlier and more frequent in bipolar disorder, type I? Nord J Psychiatry . 2021 Oct;76(7):487–488.
   PubMedGoogle Scholar
• Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012 May;26(5):403–420.
   PubMedGoogle Scholar
• Naguy A, Moodliar-Rensburg S, Alamiri B The long-acting injectable atypical antipsychotics-merits and demerits! CNS Spectr. 2021 Oct;26(5):442–443.
   PubMedGoogle Scholar
• Uchida S, Hiraoka S, Namiki N. Development of gummi drugs of aripiprazole as hospital formulations. Chem Pharm Bull (Tokyo). 2015;63(5):354–360.
   PubMedGoogle Scholar
• Fagiolini A, Forgione RN, Morana B, et al. Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489–504.
   PubMed Web of Science ®Google Scholar
• San L, Casillas M, Ciudad A, et al. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther. 2008;14(3):203–214. DOI:10.1111/j.1755-5949.2008.00053.x
   PubMed Web of Science ®Google Scholar
• Sajatovic M, Thompson TR, Nanry K, et al. Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders. Patient Prefer Adherence. 2013;7:411–417.
   PubMed Web of Science ®Google Scholar
• van Dulmen S, Sluijs E, van Dijk L, et al. Furthering patient adherence: a position paper of the international expert forum on patient adherence based on an internet forum discussion. BMC Health Serv Res. 2008;8:47.
   PubMed Web of Science ®Google Scholar
• Domino FJ. Improving adherence to treatment for hypertension. Am Fam Physician. 2005 Jun;71(11):2089–2090.
   PubMed Web of Science ®Google Scholar
• Santschi V, Wuerzner G, Schneider MP, et al. Clinical evaluation of IDAS II, a new electronic device enabling drug adherence monitoring. Eur J Clin Pharmacol. 2007 Dec;63(12):1179–1184.
   PubMedGoogle Scholar
• Heneghan CJ, Glasziou P, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2006;1:1465–1858.
   Google Scholar
• Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006 Dec;296(21):2563–2571.
   PubMed Web of Science ®Google Scholar
• Schneider PJ, Murphy JE, Pedersen CA. Impact of medication packaging on adherence and treatment outcomes in older ambulatory patients. J Am Pharm Assoc. 2008 Jan;48(1):58–63.
   Google Scholar
• Page S, Khan T, Kühl P, et al. Patient centricity driving formulation innovation: improvements in patient care facilitated by novel therapeutics and drug delivery technologies. Annu Rev Pharmacol Toxicol. 2022 Jan 6;62:341–363. DOI:10.1146/annurev-pharmtox-052120-093517
   PubMedGoogle Scholar
• Crump C, Sundquist K, Winkleby MA, et al. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry. 2013 Jul 17;70(9):931. DOI:10.1001/jamapsychiatry.2013.1394
   PubMedGoogle Scholar
• Janssen EM, McGinty EE, Azrin ST, et al. Review of the evidence: prevalence of medical conditions in the United States population with serious mental illness. Gen Hosp Psychiatry. 2015 May;37(3):199–222.
   PubMedGoogle Scholar
• Bessonova L, Velligan DI, Weiden PJ, et al. Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey. BMC Psychiatry. 2020 Jul 6;20(1):354. DOI:10.1186/s12888-020-02767-x
   PubMedGoogle Scholar
• Samalin L, Charpeaud T, Lorabi O, et al. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection. Patient Prefer Adherence. 2010 Sep 7;4:325–334. DOI:10.2147/PPA.S7647
   PubMedGoogle Scholar